Details: The study will examine the safety and effectiveness of AMG 827 for the treatment of moderate to severe Crohn's disease. Patients will randomly receive either AMG 827 or placebo (a lookalike liquid that doesn't have any drug in it) and neither the doctor nor the patient will know what treatment is being given.
Ages Eligible for Study: 18-65 years of age
Genders Eligible for Study: Male and females
Contact Information: http://www.amgencrohnsdiseasestudy.com or http://clinicaltrial...how/NCT01150890 or call 1-866-57AMGEN (1-866-572-6436)
Principal investigator: Multiple investigators